谢立信主要从事眼科角膜病、白内障的应用基础和临床诊治研究。在角膜病领域，他率先提出并论证了 角膜内皮细胞功能评估的新理论和新标准；组织完成我国首个角膜病流行病学调查，提出多项创新理 论，推动手术变迁；发明我国首个具有独立知识产权的眼内植入环孢素缓释药物；研发角膜活性保存 液、生物角膜、人工角膜等系列产品，缓解了我国角膜供体匮乏问题。在白内障领域，他率先引进超声 乳化白内障联合人工晶体植入微创手术，创新婴幼儿白内障手术方式。他创建山东省眼科研究所，经过 34年发展，现拥有青岛眼科医院、山东省眼科医院（济南）两家三级甲等专科医院，是我国主要眼科中 心之一。 "这个奖，不仅是对我个人成绩的肯定，也是对我团队的认可。我们收获的不只是奖项，更重要的是， 这彰显着中国新时代创造力得到了充分发挥。"谢立信在获奖感言中表示，20年前，他与吴老结识；20 年后，他站在这里，所做的工作得到了认可，这或许是历史的巧合。他83岁了，仍会在医疗、教学、科 研上更加努力，回报社会与这份荣誉。 新京报讯（记者王卡拉）近日在首都医科大学学术报告厅举行的2025年度吴阶平医学奖、吴阶平医药创 新奖颁奖典礼上，中国工程院院士、肿瘤学专家、天津医 ...

新华社北京12月10日电 日前，第二届中国呼吸健康大会在广州举行。本次大会以"中西医协同·产学 研创新：共筑呼吸健康新格局"为主题，由中国工程院院士钟南山、张伯礼共同担任大会主席，汇聚了 包括中国科学院院士徐涛在内的近2000名呼吸病学、中医药学等领域的产学研代表，围绕呼吸系统疾 病"筛、防、诊、治、康"全周期管理展开深度对话和成果展示。 多位院士表示，医学创新关键在于要能为临床实践带来切实改变，要推动科研成果真正惠及百姓， 服务人民健康。 开幕式上，中国工程院院士钟南山着重强调医学融合与科技创新的核心价值。他指出，创新不仅局 限于颠覆性理论或产品，关键在于能否为临床实践带来切实改变。特别是在重大疾病防治方面，学科优 势互补与科研成果高效转化是医学进步的关键。呼吸健康事关民生与公共卫生安全，要面向人民健康， 研发推广适合中国国情的简便、价廉、有效的技术与方案。 "党的二十届四中全会相关部署为卫生健康事业指明了方向，强调呼吸健康是健康中国战略的重要 组成部分。"中国工程院院士张伯礼围绕"中西医协同"这一核心主题，指出"中西医协同"并非简单叠 加，而是优势互补、深度融合，需共同探索临床诊疗的新思路、新方法，让科研 ...

Core Insights - The 2025 "Honorary Doctors" and "National Famous Doctors" awards highlight the achievements of Chinese medical professionals in overcoming difficult medical challenges and advancing medical technology and research [1][2][3] Group 1: Medical Innovation - Medical innovation is rooted in clinical practice, emerging from every patient consultation and surgical breakthrough [2][3] - The focus of medical innovation is to address patient pain and improve their quality of life, rather than merely pursuing advanced technology for its own sake [2][3] Group 2: Clinical Practice and Patient Care - Clinical innovation is driven by the need to enhance surgical precision, reduce recovery time, and optimize patient experience [3][5] - Successful case studies, such as the development of a minimally invasive eye surgery technique, demonstrate the impact of clinical innovation on patient outcomes [3][5] Group 3: Future Directions in Healthcare - The integration of artificial intelligence in medicine is reshaping healthcare delivery, extending the role of doctors beyond hospitals to community and home settings [6] - Key future pillars of medical development include precision prevention, innovative drugs, minimally invasive interventions, and organ transplantation [6]

Group 1 - The Beijing Municipal Government has launched the "Beijing Action Plan for Promoting the Transformation of Scientific and Technological Achievements (2025-2027)" to enhance medical innovation and research [1] - The Beijing Municipal Health Commission has initiated an excellent clinical research program for research-type wards, investing 200 million yuan to support 30 projects across 25 hospitals, focusing on 12 key diseases [1] - The Health Commission has developed three governance tools to analyze disease burden, compare domestic and international treatment levels, and identify unmet clinical needs, resulting in the identification of 100 major medical technology issues in the capital [1] Group 2 - In October 2022, Beijing introduced a pilot program for medical innovation and achievement transformation at hospitals, with 24 pilot projects covering innovative medical devices, drugs, and digital therapies [2] - The pilot projects include internationally pioneering solutions such as 3D-printed skull plates and new therapies for stroke and mental health [2] - The government has released a 2.0 version of the pilot program, emphasizing increased funding from hospitals, accelerated data value transformation, and improved decision-making processes to enhance the efficiency of technology transfer [2]

Core Insights - The 8th China International Import Expo (CIIE) opened on November 5, showcasing Roche's commitment to innovation and life protection with over 40 products and diverse innovative solutions [1][3] - Roche's participation highlights the importance of CIIE as a strategic platform for foreign enterprises to engage with the Chinese market and share global innovations [5] Group 1: Roche's Participation - Roche Pharmaceuticals held the "2025 Roche Pharmaceuticals 8th CIIE Opening Ceremony" and presented its complete pharmaceutical value chain in China for the first time [1] - The company showcased more than 10 products that will soon be launched in China, covering various disease areas including breast cancer, hematology, neuroscience, ophthalmology, immunology, cardiovascular, and metabolism [5] Group 2: CIIE's Role - The CIIE serves as a key platform for China to open its market and promote global cooperation, focusing on high-quality exhibitors and innovative products [3] - Over the past eight years, the CIIE has facilitated the transformation of nearly 15 Roche global innovative drugs from exhibits to market-ready products, benefiting Chinese patients [5] Group 3: Innovative Solutions - Roche's exhibition included immersive creative interactive installations to enhance public understanding of medical innovations and humanistic care [5] - The company also presented various AI solutions that span research, diagnosis, and patient management, aiming to empower the entire diagnostic and treatment process [5]

Core Insights - Fudan University has received approval to establish the Hongqiao Medical Innovation Park, which is expected to be completed around 2030, located in the Hongqiao International Central Business District [1] - The park will serve as a comprehensive innovation hub integrating education, research, industry, and services, aiming to align with world-class medical centers and enhance the integration of medical and industrial resources [1][2] Group 1 - The Hongqiao Medical Innovation Park will consist of five plots and is strategically positioned within the core area of the Hongqiao International Open Hub [1] - The park aims to create an integrated experimental zone for medical education and technology talent, a full-chain gathering area for the biopharmaceutical industry, and high-level international medical services [1][2] Group 2 - The establishment of the park is not merely an expansion of space but a strategic move to position Fudan University as a leader in new medical disciplines and interdisciplinary integration [2] - The park will focus on cutting-edge fields such as biomedicine, artificial intelligence, and biomedical engineering, facilitating seamless connections between basic research, clinical transformation, and industrial application [2] Group 3 - The park will leverage Fudan University's multidisciplinary strengths to advance in emerging fields like intelligent medicine and brain-machine interfaces, while also expanding into areas such as genetic medicine, cell and gene therapy, and vaccine safety [3]

Group 1 - The 8th China International Import Expo (CIIE) opened on November 5, showcasing Roche's commitment to innovation and life protection with over 40 products and innovative solutions [1][2] - Roche's participation in CIIE has facilitated the transformation of nearly 15 global innovative drugs into marketable products in China, benefiting local patients [2] - Roche's exhibition includes upcoming products in various disease areas such as breast cancer, hematology, neuroscience, ophthalmology, immunology, cardiovascular, and metabolism [2][3] Group 2 - The CIIE serves as a key platform for China's market openness and global cooperation, emphasizing high-quality exhibitors and innovative products [2] - Roche's exhibition features immersive interactive installations and a "healing space" to enhance public engagement with medical innovations and humanistic care [2] - During the expo, Roche and its partners held over ten conferences focusing on digital healthcare and medical innovation, showcasing the latest clinical advancements and cross-sector collaboration [3]

Core Viewpoint - The article highlights the advancements in medical technology, particularly brain-computer interface (BCI) technology, and its applications in patient rehabilitation, as well as the importance of healthy lifestyle habits in preventing cardiovascular diseases. Group 1: Brain-Computer Interface Technology - BCI technology aims to reconnect the disrupted communication pathways between the brain and limbs in patients with conditions like stroke, enabling them to regain motor functions [7][8] - The technology involves capturing brain signals through invasive methods (implanting electrodes) or non-invasive methods (using special helmets to read brain waves) [7][8] - Current research focuses on helping patients achieve motor rehabilitation, language reconstruction, and visual restoration, allowing paralyzed patients to control devices like robotic arms or wheelchairs through thought [8][9] Group 2: Cardiovascular Health and Lifestyle - Cardiovascular diseases are a major health threat in China, closely linked to poor lifestyle choices such as high salt, oil, and sugar intake, excessive alcohol consumption, smoking, and lack of sleep [11][12] - Recommendations for improving cardiovascular health include reducing salt intake to less than 5 grams per day, oil to 25-30 grams, and sugar to less than 25 grams, while increasing the consumption of vegetables, fruits, and whole grains [12] - Emphasizing the importance of integrating physical activity into daily routines and maintaining mental well-being as part of a healthy lifestyle [12] Group 3: Medical Ethics and Education - The cultivation of medical ethics and skills is essential for healthcare professionals, with a focus on integrating ethical training with clinical practice [14][15] - Young medical professionals should be encouraged to develop empathy, communication skills, and a strong sense of responsibility towards patients [15] - The article advocates for a supportive environment for healthcare workers, emphasizing the need for continuous learning and experience accumulation to enhance patient care [19]

Core Viewpoint - The establishment of the Central Plains Medical Science City aims to create a leading hub for biomedical innovation and health industry in Henan Province, integrating research, production, and market applications [1][2][3]. Group 1: Development and Growth - The Central Plains Medical Science City has signed 88 projects and registered 263 biomedical enterprises, attracting major global players like BD Medical [4]. - The city has successfully integrated various resources, including 12 academicians and 500 research personnel, to form a high-end medical research talent pool [4]. - A total of 185 billion yuan has been pledged for biomedical development funds, enhancing financial support for the industry [4]. Group 2: Innovation and Technology - The city is leading advancements in key technologies such as gene therapy, smart healthcare, and new drug development, establishing itself as a national and global benchmark for medical innovation [3][7]. - The introduction of a nanoenzyme production line demonstrates significant economic potential, with an annual output value of 100 million yuan from a relatively small production capacity [5][6]. - The "organ-on-a-chip" technology developed by a local company showcases the integration of AI and biomedical applications, with collaborations with major pharmaceutical companies [7]. Group 3: Infrastructure and Services - The city has established 11 clinical research institutes and several public service platforms to support biomedical research and development [6]. - Comprehensive infrastructure improvements, including a robust road network and high living standards for talent, have been implemented to support the growing industry [6]. - A streamlined service mechanism has been established to facilitate project registration, inspection, and approval processes, enhancing operational efficiency for enterprises [6]. Group 4: Future Prospects - The Central Plains Medical Science City is on track to become a globally influential center for medical innovation, aiming to integrate traditional and modern medicine [8]. - The city is positioned to become a world-class hub for the biomedical health industry, with ongoing efforts to attract leading enterprises and innovative teams [8].

Core Viewpoint - The National Health Commission has banned the use of lymphatic-venous anastomosis (LVA) for treating Alzheimer's disease due to a lack of clinical evidence supporting its safety and efficacy [1][2][4] Group 1: Regulatory Actions - The National Health Commission issued notifications prohibiting the use of LVA for Alzheimer's treatment and also banned the use of jejunoileal anastomosis for type 2 diabetes [1] - The decision was based on evaluations that found insufficient clinical evidence and a lack of clear indications and contraindications for the LVA procedure [2] Group 2: Medical Innovation Concerns - The application of LVA for Alzheimer's treatment is considered an off-label use, lacking theoretical and clinical trial support, which raises concerns about the safety of patients [3] - There is a growing trend of medical institutions promoting unverified technologies as innovative treatments, which can mislead patients and exploit their desperation for effective therapies [3][4] Group 3: Ethical and Research Standards - The use of unproven techniques in clinical settings blurs the line between clinical research and clinical application, leading to potential patient exploitation [2] - Ethical guidelines require that clinical research undergoes proper design and informed consent, which many institutions have failed to adhere to in the case of LVA [2][3]